Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

Real-world studies have evaluated the use of anticoagulants in obese patients with
nonvalvular atrial fibrillation (NVAF), but they have been limited by sample size or the use of …

Background Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …

Background Atrial fibrillation and heart failure are combined risk factors for thromboembolic
events. Obese and morbidly obese individuals have been underrepresented in clinical trials …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …

Background: In patients with venous thromboembolism (VTE), warfarin had been considered
standard of care until the new direct oral anticoagulants (DOACs) were developed. Studies …

Safety and efficacy of direct oral anticoagulants (DOAC) in low weight patients with atrial
fibrillation (AF) is unclear due to few low body weight patients enrolled in clinical trials. To …

Background: The International Society of Thrombosis and Haemostasis recommends
avoiding direct oral anticoagulants (DOACs) in morbidly obese patients with a body mass …

Background: Guidelines caution against the use of non–vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …

Background Obese patients are underrepresented in clinical trials assessing the
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …